Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin
European Journal of Cancer2018Vol. 106, pp. 24–33
Citations Over TimeTop 10% of 2018 papers
Richard Hubner, Antonio Cubillo, Jean‐Frédéric Blanc, Davide Melisi, Daniel D. Von Hoff, Andrea Wang‐Gillam, Li‐Tzong Chen, Claus Becker, Khalid Mamlouk, Bruce Belanger, Yoojung Yang, Floris A. de Jong, Jens T. Siveke
Abstract
In the NAPOLI-1 study, HRQOL was maintained with nal-IRI+5-FU/LV in patients with metastatic pancreatic adenocarcinoma previously treated with a gemcitabine-based regimen, while survival was significantly extended.
Related Papers
- → Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer(1998)992 cited
- → Treatment of a Gilbert's Syndrome Patient with Irinotecan, Leucovorin and 5-Fluorouracil(2005)2 cited
- Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.(2001)
- Combination chemotherapy of irinotecan combined with bolus 5-fluorouracil, continuous infusion 5-fluorouracil, and high dose leucovorin every two weeks in recurrent or metastatic colorectal cancer.(2003)
- → Oxaliplatin (L-OHP) combined with irinotecan (CPT-11), leucovorin (LV) and fluorouracil (5-FU) compared with irinotecan, leucovorin and fluorouracil as first-line treatment for metastatic colorectal cancer (MCC): Preliminary results of a multicenter randomized phase III trial(2004)2 cited